

Anne S Strik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1858808/publications.pdf>

Version: 2024-02-01

21
papers

683
citations

759055

12
h-index

887953

17
g-index

21
all docs

21
docs citations

21
times ranked

1044
citing authors

#	ARTICLE	IF	CITATIONS
1	A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 650-660.	0.9	116
2	Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1128-1134.	1.9	106
3	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 15-37.	1.6	91
4	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 145-154.	0.6	61
5	Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 404-412.	3.7	56
6	Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 453-458.	0.6	49
7	Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 429-439.	1.3	40
8	DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S063-S063.	0.6	34
9	Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?. <i>AAPS Journal</i> , 2018, 20, 99.	2.2	29
10	Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 202-211.	1.0	26
11	Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 507-522.	1.9	20
12	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 700-706.	0.6	16
13	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 289-294.	1.0	13
14	Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 885-891.	1.3	8
15	Golimumab for moderate to severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 401-406.	1.4	7
16	Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2049-2053.	0.2	7
17	Unchanged Infliximab Serum Concentrations After Switching from the Originator Infliximab to the Biosimilar CT-P13 in Patients with Quiescent Crohn's Disease: A Prospective Study. <i>Gastroenterology</i> , 2017, 152, S66.	0.6	4
18	Editorial: anti-tumour necrosis factor antibodies—can efficacy be regained? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1474-1475.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1041-1042.	1.9	0
20	OP005 Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S004-S004.	0.6	0
21	Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. <i>The Cochrane Library</i> , 2018, , .	1.5	0